Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...

(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ...

As part of the agreements, Mainz Biomed said Quest Diagnostics will provide clinical trial and laboratory services to support its ReconAAsense Food and Drug Administration pivotal study of ColoAlert.

Mainz Biomed announced the pricing of an $8 million ... s ongoing operations and position in the molecular genetics diagnostics industry, as it continues its pivotal FDA clinical study for US ...

“We are excited by the opportunity to work with Quest Diagnostics,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Quest is a leader in cancer diagnostics and knows how ...

biomedical devices, sensors, instrumentation and diagnostics, computational engineering and modeling, medical imaging and analysis, or in a student's chosen area of interest. Faculty in the Biomedical ...

(“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today an agreement with Quest Diagnostics (NYSE:DGX), a ...

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...